OncoMatch/Clinical Trials/NCT07465835
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Is NCT07465835 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ELA026 for t cell malignancies.
Treatment: ELA026 — This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — relapsed/refractory
R/R following any line of prior therapy (participants with CTCLs should have received at least 2 prior lines of systemic therapy for R/R CTCL)
Cannot have received: allogeneic hemopoietic stem cell transplant
Exception: allowed if >100 days prior to first dose and not currently receiving systemic immunosuppressive therapy
Allogeneic hemopoietic stem cell transplant within 100 days prior to the first dose of ELA026 and currently receiving systemic immunosuppressive therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START, Midwest · Grand Rapids, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify